Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Sep;37(9):2009–2016. doi: 10.1128/aac.37.9.2009

In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.

G J Malanoski 1, L Collins 1, C Wennersten 1, R C Moellering Jr 1, G M Eliopoulos 1
PMCID: PMC188112  PMID: 8239623

Abstract

The in vitro activity of biapenem, a new carbapenem previously designated L-627, was compared with those of imipenem and several other antimicrobial agents against 771 clinical bacterial isolates. Against gram-positive organisms, biapenem was found to be approximately as active as imipenem, inhibiting 90% of isolates of most species at concentrations within one dilution of the MIC of imipenem for 90% of the isolates. Against gram-negative organisms and Bacteroides fragilis, biapenem was at least as active as and often more active than imipenem, with MICs for 90% of the isolates two- to eightfold lower than those of imipenem.

Full text

PDF
2009

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Catchpole C. R., Wise R., Thornber D., Andrews J. M. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother. 1992 Sep;36(9):1928–1934. doi: 10.1128/aac.36.9.1928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Klimm K., Ferraro M. J., Jacoby G. A., Moellering R. C., Jr Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):481–488. doi: 10.1016/0732-8893(89)90082-5. [DOI] [PubMed] [Google Scholar]
  4. Iaconis J. P., Sanders C. C. Purification and characterization of inducible beta-lactamases in Aeromonas spp. Antimicrob Agents Chemother. 1990 Jan;34(1):44–51. doi: 10.1128/aac.34.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Mitsuhashi S. In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria. J Antimicrob Chemother. 1983 Dec;12 (Suppl 500):53–64. doi: 10.1093/jac/12.suppl_d.53. [DOI] [PubMed] [Google Scholar]
  6. Petersen P. J., Jacobus N. V., Weiss W. J., Testa R. T. In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I. Antimicrob Agents Chemother. 1991 Jan;35(1):203–207. doi: 10.1128/aac.35.1.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ubukata K., Hikida M., Yoshida M., Nishiki K., Furukawa Y., Tashiro K., Konno M., Mitsuhashi S. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother. 1990 Jun;34(6):994–1000. doi: 10.1128/aac.34.6.994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES